Obesity Medicine

Your daily dose of the clinical news you may have missed.

Sandra Christensen, MSN, ARNP, gives her top strategies on patient selection for treatment with antiobesity medications and how to choose the right drugs for patients.

Your daily dose of the clinical news you may have missed.

Waist-to-hip ratio was more powerfully and consistently associated with risk of all-cause mortality than BMI or FMI, but can it replace BMI as a clinical indicator?

The new app is designed to help persons with diabetes understand how food and activity impact blood glucose levels and to revise behavior accordingly.

An intensive parent-support early childhood obesity intervention program led to better weight status outcomes in the long-term compared to standard therapy, report study authors.

Obesity specialist Sandra Christensen, MSN, ARNP, compares the benefits and drawbacks among older antiobesity drugs and newer GLP-1RAs liraglutide and semaglutide 2.4 mg.

Obesity specialist Sandra Christensen, MSN, ARNP, details the differences between older antiobesity medications and newer GLP-1RAs liraglutide and semaglutide 2.4 mg.

The selective aldosterone synthase inhibitor will move into late stage clinical trials, a nod to the potential for a first-in-class agent targeting aldosterone.

The class of GLP-1 receptor agonists and similar agents, originally approved to treat type 2 diabetes, also reduce body weight and reduce CVD risk; what's next?

Your daily dose of clinical news you may have missed.

Elevated inflammation, rather than depression, may drive poor weight loss outcomes in patients with obesity following bariatric surgery, suggest authors of new study.

Your daily dose of clinical news you may have missed.

Your daily dose of clinical news you may have missed.

Atrial fibrillation prevalence is rising across socioeconomic strata globally, the new analysis finds, with effects of BMI, ETOH, and sedentary behavior shifting as key drivers.

Three key drivers of the perennial increase in OA prevalence are population growth, aging, and obesity, said authors of the analysis for the Global Burden of Disease study.

A daily dose of clinical news on Patient Care you may have missed.

ESC Congress 2023. The results of STEP-HFpEF could "change the nature of the conversation about the role of obesity in HFpEF," said PI Mikhail Kosiborod, MD.

Before creating a nutrition plan for patients with obesity, clinicians should first understand their eating patterns, says one obesity expert.

More than 90 million adults in the US with overweight/obesity are candidates for weight loss treatment with semaglutide 2.4 mg, according to a new study.

A daily dose of clinical news on Patient Care you may have missed.

Dr Alina Elperin details which medications primary care clinicians should be prepared to prescribe patients with obesity to help prevent cardiovascular disease, here.

Excess CVD mortality among Black vs White adults was diminished after control for behavior/metabolic factors and negligible after adjustments for SDOH, a new study reveals.

Postmenopausal women who consumed 1 or more sugary drinks daily had a nearly 2-fold increased risk of liver cancer in a study of more than 98 000.

Most Americans are aware of the hot prescription drugs associated with weight loss and many are interested in using them. But access and administration are problematic.

Internist and obesity medicine specialist Alina Elperin, MD, details the most common cardiovascular complications that she has observed in patients with obesity.

Obesity medicine specialist and internist Alina Elperin, MD, shares why screening for obstructive sleep apnea and metabolic disease in patients with obesity is crucial.

In adults with obesity or overweight plus comorbidities but without T2D once-weekly tirzepatide was associated with significant and durable weight loss vs placebo.

Methods proven to prevent ASCVD may fall short in certain populations if the impacts of SDOH are not closely monitored. The ACC/AHA provide considerations for 7 health domains.